• LAST PRICE
    5.8500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    4.6000/ 1
  • Ask / Lots
    6.9100/ 2
  • Open / Previous Close
    0.0000 / 5.8500
  • Day Range
    ---
  • 52 Week Range
    Low 2.0600
    High 17.2850
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 5.8
TimeVolumeANNX
09:32 ET8245.86
09:35 ET2005.65
09:37 ET2005.73
10:13 ET1005.83
10:15 ET1005.73
10:27 ET1005.71
10:36 ET8735.99
10:54 ET1005.695
11:43 ET1005.74
11:48 ET1975.9738
11:50 ET2005.97
12:01 ET2915.7556
12:12 ET2005.96
12:15 ET2005.95
12:17 ET2005.96
12:19 ET1005.91
12:28 ET1005.7675
12:32 ET2005.96
12:48 ET4015.79
12:57 ET1005.87
01:00 ET25125.85
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesANNX
Annexon Inc
278.6M
-1.7x
---
United StatesCBAY
Cymabay Therapeutics Inc
279.4M
-2.6x
---
United StatesRAIN
Rain Therapeutics Inc
280.8M
-3.0x
---
United StatesATNM
Actinium Pharmaceuticals Inc
280.3M
-8.5x
---
United StatesTYRA
Tyra Biosciences Inc
284.8M
-5.4x
---
United StatesSTOK
Stoke Therapeutics Inc
289.0M
-2.8x
---
As of 2022-11-28

Company Information

Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing complement medicines for patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Its pipeline includes three clinical-stage assets across three therapeutic franchises: Autoimmune, Neurodegeneration and Ophthalmology. Its lead candidate, ANX005, is a monoclonal antibody formulated for intravenous administration for several autoimmune indications. ANX005 is being evaluated in a Phase II/III clinical trial for the treatment of patients with Guillain-Barre Syndrome and a Phase II trial in patients with warm autoimmune hemolytic anemia. It ANX009 clinical candidate is a subcutaneous formulation of an antigen-binding fragment, which is evaluates in a Phase I trial. It is also developing ANX005, which is in Phase II trials in Huntington’s disease and amyotrophic lateral sclerosis. The Company's ANX007 program is a Fab formulated.

Contact Information

Headquarters
1400 SIERRA POINT PARKWAY BLDG C SUITE 200BRISBANE, CA, United States 94005
Phone
650-822-5500
Fax
650-636-9773

Executives

Independent Chairman of the Board
Thomas Wiggans
President, Chief Executive Officer, Director
Douglas Love
Chief Financial Officer, Executive Vice President
Jennifer Lew
Executive Vice President, Chief Scientific Officer
Larry Mattheakis
Executive Vice President, Chief Business Officer
Michael Overdorf

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$278.6M
Revenue (TTM)
$0.00
Shares Outstanding
47.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-3.36
Book Value
$6.01
P/E Ratio
-1.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.